Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

82 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Nielsen LL, Young AA, Parkes DG. Nielsen LL, et al. Among authors: parkes dg. Regul Pept. 2004 Feb 15;117(2):77-88. doi: 10.1016/j.regpep.2003.10.028. Regul Pept. 2004. PMID: 14700743 Review.
Amylin: Pharmacology, Physiology, and Clinical Potential.
Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Hay DL, et al. Among authors: parkes dg. Pharmacol Rev. 2015 Jul;67(3):564-600. doi: 10.1124/pr.115.010629. Pharmacol Rev. 2015. PMID: 26071095 Free article. Review.
Bifunctional PEGylated exenatide-amylinomimetic hybrids to treat metabolic disorders: an example of long-acting dual hormonal therapeutics.
Sun C, Trevaskis JL, Jodka CM, Neravetla S, Griffin P, Xu K, Wang Y, Parkes DG, Forood B, Ghosh SS. Sun C, et al. Among authors: parkes dg. J Med Chem. 2013 Nov 27;56(22):9328-41. doi: 10.1021/jm401418s. Epub 2013 Nov 6. J Med Chem. 2013. PMID: 24144329
Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.
Parkes DG, Mace KF, Trautmann ME. Parkes DG, et al. Expert Opin Drug Discov. 2013 Feb;8(2):219-44. doi: 10.1517/17460441.2013.741580. Epub 2012 Dec 12. Expert Opin Drug Discov. 2013. PMID: 23231438 Review.
Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.
Tatarkiewicz K, Smith PA, Sablan EJ, Polizzi CJ, Aumann DE, Villescaz C, Hargrove DM, Gedulin BR, Lu MG, Adams L, Whisenant T, Roy D, Parkes DG. Tatarkiewicz K, et al. Among authors: parkes dg. Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E1076-86. doi: 10.1152/ajpendo.00479.2010. Epub 2010 Oct 5. Am J Physiol Endocrinol Metab. 2010. PMID: 20923958 Free PMC article.
Insights into amylin-leptin synergy.
Trevaskis JL, Parkes DG, Roth JD. Trevaskis JL, et al. Among authors: parkes dg. Trends Endocrinol Metab. 2010 Aug;21(8):473-9. doi: 10.1016/j.tem.2010.03.006. Epub 2010 Apr 21. Trends Endocrinol Metab. 2010. PMID: 20413324 Review.
Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, Parkes DG, Young AA. Gedulin BR, et al. Among authors: parkes dg. Int J Pharm. 2008 May 22;356(1-2):231-8. doi: 10.1016/j.ijpharm.2008.01.015. Epub 2008 Jan 17. Int J Pharm. 2008. PMID: 18291606
Investigation of exenatide elimination and its in vivo and in vitro degradation.
Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Copley K, et al. Among authors: parkes dg. Curr Drug Metab. 2006 May;7(4):367-74. doi: 10.2174/138920006776873490. Curr Drug Metab. 2006. PMID: 16724926
Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, Gedulin BR, Flanagan SD, Jodka CM, Hoyt JA, McCowen KM, Parkes DG, Anderson CM. Hargrove DM, et al. Among authors: parkes dg. Regul Pept. 2007 Jun 7;141(1-3):113-9. doi: 10.1016/j.regpep.2006.12.021. Epub 2007 Jan 11. Regul Pept. 2007. PMID: 17292977
Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action.
Levy OE, Jodka CM, Ren SS, Mamedova L, Sharma A, Samant M, D'Souza LJ, Soares CJ, Yuskin DR, Jin LJ, Parkes DG, Tatarkiewicz K, Ghosh SS. Levy OE, et al. Among authors: parkes dg. PLoS One. 2014 Feb 4;9(2):e87704. doi: 10.1371/journal.pone.0087704. eCollection 2014. PLoS One. 2014. PMID: 24503632 Free PMC article.
82 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page